Chelsie Derman

Allergy treatment use increases postpartum depression risk in women with allergic rhinitis, a study found.

Q1 2025 featured several regulatory updates in psychiatry, such as esketamine as the first monotherapy for treatment-resistant depression.

Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

HCPLive spoke with Levine about what is moving in the psychiatry pipeline and what is to come.

Aquestive’s Anaphylm study showed positive pharmacokinetic results in children and adolescents, supporting its FDA submission.

March Allergy Updates: FDA approved the first biosimilar for omalizumab, epicutaneous and oral immunotherapy trials showed promise, and experts discussed allergy trends.

TSND-201 (methylone) met its primary endpoint in the phase 2 IMPACT-1 trial, showing rapid, significant PTSD symptom improvement with a good safety profile.

A study links daily discrimination to greater depression and anxiety rates, with marginalized groups facing greater mental health risks across the US.

A 2024 survey finds that most healthcare providers believe quality of life should be considered as much as symptom control when managing bipolar I disorder and schizophrenia.

A study found omalizumab enables faster, safer desensitization in children with food allergies, improving oral immunotherapy outcomes and reducing reactions.

A meta-analysis of 27 trials found no increased risk of suicide or self-harm with GLP-1 RAs, supporting their safety for diabetes and obesity management.

A phase 1 study found neffy nasal spray provides effective epinephrine absorption in children, supporting its role as a needle-free anaphylaxis treatment.

Despite low food allergy prevalence in adults (0.31%), anaphylaxis remains common, highlighting the need for better diagnosis and emergency treatment.

A study found many anaphylaxis patients didn’t receive adrenaline, the first-line treatment. Adrenaline use correlated with better outcomes in adults and children.

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

New study highlights discrepancies in anaphylaxis severity scoring, emphasizing the need for a unified classification to improve treatment.

A new study found that the time it takes to diagnose alpha-gal syndrome has improved from 5.3 years to 28 days since 2011, but disparities remain based on education level.

A study found that genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.

Patients with hereditary angioedema report greater rates of autoimmune diseases, allergies, and asthma than the general population, highlighting key comorbidities.

A study highlights how food allergies impact adults' mental health and social lives, revealing anxiety, isolation, and the need for better support systems.

Lugar spoke with HCPLive about when to refer patients with suspected ISM to an allergist, highlighting allergic manifestations, diagnostic clues, and misconceptions.

HCPLive spoke with Lugar on indolent systemic mastocytosis’ allergic manifestations and diagnostic markers.

The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.

New ACP migraine guidelines recommend adding a triptan to NSAIDs or acetaminophen for better relief. Combination therapy offers greater pain relief and fewer rescues.

A study found ceftriaxone was the most common drug to lead to anaphylaxis in children.

A new study highlights key risk factors of cold-induced anaphylaxis, including genetic markers and elevated IgE, expanding on findings from the COLD-CE study.

A narrative review reports the connection between allergies and sleep and available treatment options for both conditions.

Among 162 patients in the study, 99% reported satisfaction of sublingual immunotherapy with real grocery store food.